HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 22, 2015--
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that Dr. Marwan Sabbagh from the Barrow Neurological
Institute, Principal Investigator for the ongoing Phase 3 Steadfast
trial, will be presenting an evaluation of the Phase 2b safety study of
azeliragon 20 mg/day and 5 mg/day in support of Phase 3 dose selection
at the 8th Clinical Trials on Alzheimer’s Disease (CTAD)
conference. The oral presentation will take place on Friday, November 6
in Barcelona, Spain at 11:45 am CET (5:45 am EST).
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151022005151/en/
Source: vTv Therapeutics Inc.
Investors
The Trout Group
Josh Barer, 646-378-2948
jbarer@troutgroup.com
or
Media
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
